Clinical Trial Search

Primary: The Number of Participants Who Experianced Adverse Events and Serious Adverse Events — 5 participants

Primary: The Number of Participants With Acute Pancreatitis After ERCP as Assessed by Worsening Abdominal Pain Plus Either Elevated Amylase or Lipase 3 x Upper Limit of Normal…

Primary: Percent Heavy Drinking Days — 55.5; 65.1 percentage of days

Primary: Progression-Free Survival (PFS) — 21.8; 11.1 months — p=< 0.0001

Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion or Any Rescue Procedure for Bleeding After Randomization Following a Scheduled Procedure — 22.9…

Primary: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator — 10.9; 1.4 months — p=<0.001

Primary: Dose Limiting Toxicity (DLT) — 1 participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 2; 2; 1; 3 participants

Primary: Area Under the Concentration-time Curve of MK-0822 From Time 0 to Infinity (AUC0-∞) After Single Dose — 51.47; 32.12 μM*hr

Primary: Number of Patients With Adverse Events Receiving Testosterone Enanthate Via QST Auto-injector. — 5; 1; 0; 0 Participants

Primary: Number of Participants Who Require Preemptive HCMV Therapy — 24; 23; 9 Count of Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (TESAEs): Safety Population — 38; 4 Participants

Primary: Change in Motor Evoked Potential (MEP) Amplitude in the Tibialis Anterior Muscle at the End of Training. — -1.75; -2.01 Amplitude percentage of Mmax

Primary: Clinical Global Impression-Severity-Severe Mood Dysregulation — 4.91; 3.62; 4.30; 4.42 units on a scale — p=.58

Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…